Practice patterns of bupropion co-prescription with antipsychotic medications

Abstract Objective: Bupropion is one of the few medications with an FDA indication for smoking cessation. This is of particular significance due to the high co-morbidity of tobacco use disorder in patients with schizophrenia spectrum and other psychotic disorders. We sought to determine whether historical suggestions of bupropion’s pro-dopaminergic activity lead prescribers to withhold bupropion in populations receiving antipsychotic medications. Methods: The prevalence in clinical practice of the combination of bupropion and 10 antipsychotic formulations was determined by a computer review of the Genoa Healthcare database for all prescribers at 10 participating community mental health centers. Actual prevalence was compared with expected prevalence using the test of proportions. A Bonferroni correction for multiple comparisons was included. Results: Clozapine, p = 0.0004, and the microsphere formulation of risperidone, p = 0.0045, were prescribed with bupropion significantly less often that chance. None of the other eight antipsychotic formulations were prescribed significantly differently than chance. Conclusions: The co-prescription of bupropion and antipsychotic medication may be affected by historical misconceptions regarding bupropion’s purportedly pro-dopamine properties. Viable options for the treatment of tobacco use disorder should not be discounted prematurely in patients with schizophrenia spectrum and other psychotic disorders. We suggest further study on the safety and efficacy of the combination of bupropion and antipsychotic medication is needed.

[1]  P. Zarkowski.  Relative prevalence of 10 types of pharmacodynamic interactions in psychiatric treatment , 2020, International journal of psychiatry in medicine.

[2]  Xiufeng Xu,et al.  Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. , 2019, Journal of affective disorders.

[3]  R. Murray,et al.  Tobacco smoking and nicotine dependence in first episode and established psychosis. , 2019, Asian journal of psychiatry.

[4]  N. Benowitz,et al.  Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial , 2019, Journal of clinical psychopharmacology.

[5]  J. Derevensky,et al.  The Stimulating Nature of Gambling Behaviors: Relationships Between Stimulant Use and Gambling Among Adolescents , 2019, Journal of Gambling Studies.

[6]  D. Prabhakar,et al.  Stimulant Formulations for the Treatment of Attention-Deficit/Hyperactivity Disorder. , 2018, The primary care companion for CNS disorders.

[7]  Sheeba Varghese Gupta,et al.  Role of CYP2B6 pharmacogenomics in bupropion‐mediated smoking cessation , 2018, Journal of clinical pharmacy and therapeutics.

[8]  Huafang Li,et al.  Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers , 2018, European Journal of Drug Metabolism and Pharmacokinetics.

[9]  J. Yager,et al.  Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD. , 2018, The International journal of eating disorders.

[10]  F. Carroll,et al.  New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice , 2018, Neuropharmacology.

[11]  S. Stahl.  Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate , 2018, CNS Spectrums.

[12]  Shijie Wei,et al.  Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[13]  D. Han,et al.  Bupropion Shows Different Effects on Brain Functional Connectivity in Patients With Internet-Based Gambling Disorder and Internet Gaming Disorder , 2018, Front. Psychiatry.

[14]  F. Schifano,et al.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review , 2018, Brain sciences.

[15]  F. Kapczinski,et al.  Bipolar disorder and tobacco smoking: Categorical and dimensional clinical correlates in subjects from the Brazilian bipolar research network. , 2017, Comprehensive psychiatry.

[16]  Xiaohong Li,et al.  Prevalence of smoking in patients with bipolar disorder, major depressive disorder and schizophrenia and their relationships with quality of life , 2017, Scientific Reports.

[17]  Grant D. Huang,et al.  Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial , 2017, JAMA.

[18]  G. Harrington,et al.  Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers , 2017, The AAPS Journal.

[19]  Lauren M. Hickling,et al.  Tobacco smoking and its association with cognition in first episode psychosis patients , 2017, Schizophrenia Research.

[20]  L. Hogarth,et al.  Cigarette smoking and depression comorbidity: systematic review and proposed theoretical model , 2017, Addiction.

[21]  B. Carleton,et al.  Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study , 2017, Journal of clinical psychopharmacology.

[22]  E. Molden,et al.  Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data , 2015, Therapeutic drug monitoring.

[23]  T. J. Moore,et al.  Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. , 2014, JAMA internal medicine.

[24]  C. Davidson,et al.  Stimulant mechanisms of cathinones — Effects of mephedrone and other cathinones on basal and electrically evoked dopamine efflux in rat accumbens brain slices , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[25]  M. Thase,et al.  Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study , 2014, BMC Research Notes.

[26]  G. Martinotti,et al.  Bupropion as an Add-on Therapy in Depressed Bipolar Disorder Type I Patients With Comorbid Cocaine Dependence , 2014, Clinical neuropharmacology.

[27]  D. Nutt,et al.  Amphetamine, past and present – a pharmacological and clinical perspective , 2013, Journal of psychopharmacology.

[28]  Ulrich M. Zanger,et al.  Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance , 2013, Front. Genet..

[29]  Nicole L. Nollen,et al.  CYP2B6 and Bupropion's Smoking‐Cessation Pharmacology: The Role of Hydroxybupropion , 2012, Clinical pharmacology and therapeutics.

[30]  Sanjeev Kumar,et al.  Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. , 2011, General hospital psychiatry.

[31]  R. Lukas,et al.  Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[32]  R. Lukas,et al.  Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. , 2010, Journal of medicinal chemistry.

[33]  Maurizio Fava,et al.  The STAR*D project results: A comprehensive review of findings , 2007, Current psychiatry reports.

[34]  W. Coryell,et al.  Bupropion in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study , 2007, Journal of clinical psychopharmacology.

[35]  K. Gadde,et al.  Bupropion Treatment of Olanzapine-Associated Weight Gain: An Open-Label, Prospective Trial , 2006, Journal of clinical psychopharmacology.

[36]  J. Jefferson,et al.  Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. , 2005, Clinical therapeutics.

[37]  J. Leon,et al.  A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors , 2005, Schizophrenia Research.

[38]  R. Lukas,et al.  Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors , 2004, Molecular Pharmacology.

[39]  Alan A. Wilson,et al.  Bupropion occupancy of the dopamine transporter is low during clinical treatment , 2002, Psychopharmacology.

[40]  J. Warnock,et al.  Treatment Augmentation With Opiates in Severe and Refractory Major Depression , 1999, American Journal of Psychiatry.

[41]  C. Sánchez,et al.  Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding , 1999, Cellular and Molecular Neurobiology.

[42]  W. Potter,et al.  Psychoses associated with bupropion treatment. , 1985, The American journal of psychiatry.

[43]  Stephen M. Stahl,et al.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.

[44]  D. H. Schroeder,et al.  Clinical pharmacokinetics of bupropion: a review. , 1983, The Journal of clinical psychiatry.

[45]  D. Goode,et al.  Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type. , 1983, The Journal of clinical psychiatry.